A recent study evaluated the cost-effectiveness of BRAF inhibitors and traditional chemotherapy for the treatment of metastatic melanoma. Results suggest that compared with dacarbazine, dabrafenib and vemurafenib were not cost-effective at a willingness-to-pay threshold of $100,000/QALY. Dabrafenib was also found to be more efficient compared to vemurafenib.
- A Markov model was developed using a societal perspective
- Transition probabilities were derived from two Phase III registration trials comparing each BRAF inhibitor against dacarbazine
- Costs were obtained from literature, national databases, and Med...